CN105980403A - 肽混合物 - Google Patents

肽混合物 Download PDF

Info

Publication number
CN105980403A
CN105980403A CN201480074531.3A CN201480074531A CN105980403A CN 105980403 A CN105980403 A CN 105980403A CN 201480074531 A CN201480074531 A CN 201480074531A CN 105980403 A CN105980403 A CN 105980403A
Authority
CN
China
Prior art keywords
peptide
ras
peptides
mutation
point mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480074531.3A
Other languages
English (en)
Chinese (zh)
Inventor
乔恩·阿蒙·埃里克森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tagwax Strategy Co ltd
Original Assignee
Tagewakesi Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tagewakesi Co filed Critical Tagewakesi Co
Publication of CN105980403A publication Critical patent/CN105980403A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
CN201480074531.3A 2013-12-09 2014-12-09 肽混合物 Pending CN105980403A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13196333 2013-12-09
EP13196333.2 2013-12-09
PCT/EP2014/077033 WO2015086590A2 (en) 2013-12-09 2014-12-09 A peptide mixture

Publications (1)

Publication Number Publication Date
CN105980403A true CN105980403A (zh) 2016-09-28

Family

ID=49765823

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480074531.3A Pending CN105980403A (zh) 2013-12-09 2014-12-09 肽混合物

Country Status (24)

Country Link
US (4) US9775892B2 (enExample)
EP (5) EP3363458A3 (enExample)
JP (2) JP6781403B2 (enExample)
KR (1) KR20160097290A (enExample)
CN (1) CN105980403A (enExample)
AU (2) AU2014363643B2 (enExample)
BR (1) BR112016013138A2 (enExample)
CA (1) CA2933126A1 (enExample)
CL (4) CL2016001405A1 (enExample)
CY (1) CY1120578T1 (enExample)
DK (1) DK3079715T3 (enExample)
ES (1) ES2682038T3 (enExample)
HR (1) HRP20181213T1 (enExample)
HU (1) HUE039840T2 (enExample)
IL (1) IL246007B2 (enExample)
LT (1) LT3079715T (enExample)
MX (1) MX2016007429A (enExample)
PL (1) PL3079715T3 (enExample)
PT (1) PT3079715T (enExample)
RS (1) RS57623B1 (enExample)
RU (1) RU2016127327A (enExample)
SG (2) SG10201811172PA (enExample)
SI (1) SI3079715T1 (enExample)
WO (1) WO2015086590A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021087840A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用
CN112912387A (zh) * 2018-08-22 2021-06-04 弗雷德哈钦森癌症研究中心 靶向kras或her2抗原的免疫疗法
CN113416241A (zh) * 2020-04-09 2021-09-21 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
WO2022171032A1 (zh) * 2021-02-10 2022-08-18 上海吉倍生物技术有限公司 Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775892B2 (en) 2013-12-09 2017-10-03 Targovax Asa Peptide mixture
CN106414493A (zh) 2014-05-06 2017-02-15 塔格瓦克斯公司 包含突变的ras肽和化疗剂的肽疫苗
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
AU2018288386A1 (en) * 2017-06-22 2020-02-06 New South Wales Health Pathology Adoptive T cell therapy 2
CA3103983A1 (en) * 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
GB2596461B (en) 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
WO2021009633A1 (en) * 2019-07-12 2021-01-21 Massey University Synthetic chromatin vaccine
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
KR102515083B1 (ko) 2020-12-24 2023-03-29 부산대학교 산학협력단 폴더블 페로브스카이트 태양전지 및 이의 제조 방법
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
EP4522192A2 (en) * 2022-05-12 2025-03-19 The Johns Hopkins University Neoantigen vaccines for cancer prevention
JP2025538524A (ja) * 2022-11-22 2025-11-28 エリクサージェン セラピューティクス，インコーポレイティド 癌免疫療法のための抗原

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010382A1 (en) * 1997-08-27 1999-03-04 Norsk Hydro Asa Peptides which elicit cytotoxic t cellular immunity
WO2000066153A1 (en) * 1999-04-30 2000-11-09 Norsk Hydro Asa RAS ONCOGEN p21 PEPTIDE VACCINES
CN101448848A (zh) * 2006-03-27 2009-06-03 全球免疫股份有限公司 Ras突变及其相关组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
AU2003301021C1 (en) 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
PL1760089T3 (pl) 2005-09-05 2010-03-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US9775892B2 (en) 2013-12-09 2017-10-03 Targovax Asa Peptide mixture
CN106414493A (zh) 2014-05-06 2017-02-15 塔格瓦克斯公司 包含突变的ras肽和化疗剂的肽疫苗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010382A1 (en) * 1997-08-27 1999-03-04 Norsk Hydro Asa Peptides which elicit cytotoxic t cellular immunity
WO2000066153A1 (en) * 1999-04-30 2000-11-09 Norsk Hydro Asa RAS ONCOGEN p21 PEPTIDE VACCINES
CN101448848A (zh) * 2006-03-27 2009-06-03 全球免疫股份有限公司 Ras突变及其相关组合物和方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUNGER RE 等: "Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant", 《EXP. DERMATOL.》 *
IAN A. PRIOR等: "A comprehensive survey of Ras mutations in cancer", 《CANCER RES.》 *
MARIANNE K. GJERTSEN 等: "INTRADERMAL RAS PEPTIDE VACCINATION WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AS ADJUVANT: CLINICAL AND IMMUNOLOGICAL RESPONSES IN PATIENTS WITH PANCREATIC ADENOCARCINOMA", 《INT. J. CANCER》 *
WEDEN S. 等: "Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras", 《INT. J. CANCER》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112912387A (zh) * 2018-08-22 2021-06-04 弗雷德哈钦森癌症研究中心 靶向kras或her2抗原的免疫疗法
WO2021087840A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用
CN114651001A (zh) * 2019-11-07 2022-06-21 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用
CN114651001B (zh) * 2019-11-07 2024-12-13 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用
US12453774B2 (en) 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof
CN113416241A (zh) * 2020-04-09 2021-09-21 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
WO2022171032A1 (zh) * 2021-02-10 2022-08-18 上海吉倍生物技术有限公司 Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体

Also Published As

Publication number Publication date
BR112016013138A2 (pt) 2018-01-16
US10335473B2 (en) 2019-07-02
HRP20181213T1 (hr) 2018-10-19
JP2020023525A (ja) 2020-02-13
CL2018000226A1 (es) 2018-06-22
PT3079715T (pt) 2018-08-02
US20170189515A1 (en) 2017-07-06
EP3079715B1 (en) 2018-06-13
AU2014363643A1 (en) 2016-07-14
AU2014363643B2 (en) 2019-01-03
KR20160097290A (ko) 2016-08-17
US20180021419A1 (en) 2018-01-25
JP6781403B2 (ja) 2020-11-04
LT3079715T (lt) 2018-08-27
RS57623B1 (sr) 2018-11-30
EP3363458A2 (en) 2018-08-22
EP3363457A1 (en) 2018-08-22
US10456457B2 (en) 2019-10-29
IL246007B1 (en) 2023-01-01
CY1120578T1 (el) 2019-07-10
SG10201811172PA (en) 2019-01-30
WO2015086590A2 (en) 2015-06-18
WO2015086590A3 (en) 2015-07-30
US10596239B2 (en) 2020-03-24
MX2016007429A (es) 2016-11-11
CL2018000238A1 (es) 2018-06-22
HUE039840T2 (hu) 2019-02-28
JP2017502081A (ja) 2017-01-19
US20160331820A1 (en) 2016-11-17
EP3369432A1 (en) 2018-09-05
AU2019201937A1 (en) 2019-04-11
SI3079715T1 (en) 2018-08-31
CA2933126A1 (en) 2015-06-18
SG11201604644QA (en) 2016-07-28
PL3079715T3 (pl) 2018-11-30
EP3079715A2 (en) 2016-10-19
CL2018000232A1 (es) 2018-06-22
IL246007A (en) 2016-07-31
RU2016127327A (ru) 2018-01-23
AU2019201937B2 (en) 2020-05-28
EP3363458A3 (en) 2018-11-07
CL2016001405A1 (es) 2017-03-24
US9775892B2 (en) 2017-10-03
ES2682038T3 (es) 2018-09-18
EP3357505A1 (en) 2018-08-08
US20170326218A1 (en) 2017-11-16
DK3079715T3 (en) 2018-09-17
IL246007B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
AU2019201937B2 (en) A peptide mixture
CN107922472A (zh) Ras蛋白的突变的片段
JP5787752B2 (ja) 抗腫瘍免疫療法
JP2005533000A (ja) Ｍｄａ−７に関与する免疫誘導を増強する方法
CN108348586B (zh) 经修饰的酵母-Brachyury免疫治疗组合物
EP3840767A1 (en) Peptides
KR20220126679A (ko) Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물
CN103965360A (zh) Ny-eso-1抗原及其在肿瘤免疫治疗中的应用
WO2024052542A2 (en) A peptide cocktail
WO2025042915A1 (en) Cell therapy methods using regulatory cells stimulated with interleukin-33 and interleukin-2
ITMI20061950A1 (it) Effetto antimetastatico in condizioni patologiche delle cellule umane

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Norway lussac

Applicant after: TARGOVAX ASA

Address before: Oslo, Norway

Applicant before: TARGOVAX ASA

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230106

Address after: Norway lussac

Applicant after: Tagwax Strategy Co.,Ltd.

Address before: Norway lussac

Applicant before: TARGOVAX ASA

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160928